Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15800308 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
Conditions: Drug/Agent Toxicity by Tissue/Organ;   Lung Cancer;   Oral Complications;   Radiation Toxicity
Interventions: Biological: filgrastim;   Drug: amifostine trihydrate;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: radiation therapy

Indicates status has not been verified in more than two years